Duloxetine is a dual serotonin and norepinephrine reuptake inhibitor. It was originally discovered in 1993 and developed by Eli Lilly and Company as LY248686. Duloxetine first received approval from the FDA in August, 2004 as Cymbalta for the treatment of Major Depressive Disorder. It has since received approval for a variety of indications including the tre...
Indicated for:
1) Management of Major Depressive Disorder.
2) Management of Generalized Anxiety Disorder.
3) Management of diabetic peripheral neuropathy.
4) Management of fibromyalgia.
5) Management of chronic musculoskeletal pain.
6) Management of osteoarthritis of the knee in adults.
7) Management of chronic lower back pain in adults.
...
Yangsan Pusan National University Hospital, Mulgeum, Korea, Republic of
Beth Israel Deaconess Medical Center for Autonomic and Peripheral Nerve Disorders, Boston, Massachusetts, United States
Washington University School of Medicine, St. Louis, Missouri, United States
University of Rochester, Rochester, New York, United States
Hospital del Mar, Barcelona, Spain
Fudan University Cancer center, Shanghai, Shanghai, China
Mugla Education and Research Hospital, Muğla, Turkey
Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
Northwestern University, Chicago, Illinois, United States
Research Cinic for Functional Disorders, Aarhus, Denmark
National cancer institute, Cairo, Egypt
Montefiore Medical Center, Bronx, New York, United States
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.